… P2Y12 inhibitor therapy, our analysis did also show that patients who continued with aspirin
were … higher in the P2Y12 monotherapy trials as compared to the aspirin monotherapy trials. …

… of acetylsalicylic acid and a P2Y12 platelet receptor inhibitor, … P2Y12 receptor inhibitor and
maintaining acetylsalicylic acid … the digestive tract, P2Y12 inhibitors have been considered a …

… therapy of aspirin and a P2Y12 receptor inhibitor (clopidogrel… the need for more potent
P2Y12 inhibitors. We then describe … We try to rationalize the use of different P2Y12 inhibitors in …

… The other studies of the first group have shown that P2Y12 inhibitor monotherapy following
… have shown that P2Y12 inhibitor monotherapy (clopidogrel or ticagrelor) vs. aspirin was …

… with aspirin alone. More recently, there has been interest in shortening DAPT duration by
stopping aspirin … and may have reduced risk of gastrointestinal bleeding compared with aspirin. …

… after randomly allocating 110 ACS patients undergoing PCI to receive either ticagrelor
monotherapy or DAPT with aspirin and ticagrelor for four weeks, with both strategies followed by …

… P2Y12 inhibitor is rarely administered alone, the target population in this study was limited to
septic patients using aspirin. … After that, the patients were divided into aspirin-alone group or …

… In addition to the previously mentioned analysis by aspirin dose of the CURE data, comparing
clopidogrel plus aspirin with aspirin alone in patients with non–ST-segment elevation ACS …

… inhibitors, aspirin alone was the standard antiplatelet regimen post-MI. The CURE trial compared
clopidogrel and aspirin (DAPT) to aspirin … events compared with aspirin in both trials. In …

… w17 More potent P2Y12 inhibition shifts the curve to the right with a resultant increase in the
… hepatic metabolism), polymorphisms in P2Y12 receptors or hepatic cytochromes, diabetes …